Astrazeneca Pharma India Limited · NSE:ASTRAZEN
Astrazeneca Pharma India — Shareholder Meeting (August 2022)
33 slides from Astrazeneca Pharma India's shareholder meeting presentation, Aug 8, 2022
Slide 1: 43rd Annual General Meeting
43rd Annual General Meeting Gagan Singh 8th August 2022
Slide 2: Disclaimer
DISCLAIMER This presentation by AstraZeneca Pharma India Limited (the “Company”) is solely for general information purposes only and may not be taken away, distributed, reproduced, or passed on, directly or indirectly, to any other person or published in whole or in part, in any manner. This present
Slide 3: The Levers That Enable Our Progress
The Levers That Enable Our Progress Strategic priorities Accelerate Deliver Growth & Innovative Science TA Leadership Be A Great Place To Achieve Financial Work Targets 3
Slide 4: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 Therapy Area Update 5 COVID-19 Response 6 Sustainability 7 Great Place To Work 4
Slide 5: Global 2021 performance
Global 2021 performance Continuing to deliver on our strategic objectives 5 Source: AstraZeneca Full year 2021 presentation
Slide 6: AstraZeneca: 2022-2025
AstraZeneca: 2022-2025 Industry leading double-digit growth 66 Source: AstraZeneca Full year 2021 presentation
Slide 7: CEO quote on 2021 growth trajectory
“AstraZeneca continued on its strong growth trajectory in 2021, with industry-leading R&D productivity and five of our medicines (Tagrisso, Lynparza, Calquence, Farxiga & Fasenra) crossing new blockbuster thresholds in the year. Growth was well balanced across our strategic areas of focus, and we sa
Slide 8: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 Therapy Area Update 5 COVID-19 Response 6 Sustainability 7 Great Place To Work 8
Slide 9: Macroeconomic Outlook, Healthcare, IPM
Macroeconomic Outlook1 Healthcare2,3 IPM India is predominantly an Out of Pocket (OOP) Estimated size INR 185,498 • India has registered over 44M COVID crore (USD 24.7 Billion) market infections to date1a. Over a billion people Health Expenditure Split4 - (%) have been vaccinated in the country as o
Slide 10: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 Therapy Area Update 5 COVID-19 Response 6 Sustainability 7 Great Place To Work 10
Slide 11: AstraZeneca ranks 10th and is amongst the fastest growing MNCs in IPM
AstraZeneca ranks 10th and is amongst the fastest growing MNCs in IPM* AZ India Oncology LYNPARZA TAGRISSO 2nd Fastest growing Onco. No.1 Ovarian Cancer brand in No.1 lung cancer brand in the Company in India1 the country1 country1 BRILLINTA FASENRA SYMBICORT Continues to be No.1 leading Launched in
Slide 12: Committed to impact patient lives with industry leading pipeline portfolio across TAs
Committed to impact patient lives with Industry leading pipeline portfolio across TAs Regulatory submission timeline 2022 2023 2024 2025 EMERALD 1, AEGEAN, DATPOTAMAB KUNLUN, CAMIZESTRANT HER2 LOW, GC, & ADRIATIC, BR31, Tab & R/R PEARL, PACIFIC 2 , HER2m NSCLC, DB06 NIAGARA Potomac, NILE OLYMPIA , P
Slide 13: AZ returns to strong double-digit growth
AZ returns to strong double-digit growth & poised to continue strong momentum despite generic proliferation of low-priced products in Dapagliflozin market ₹ 761.4 Cr -2% Sales Revenue Growth 26% Revenue growth excluding Dapa Financial snapshot of FY 2021-221 QoQ Sales Growth Evolution 13 Source: 1-
Slide 14: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 Therapy Area Update 5 COVID-19 Response 6 Sustainability 7 Great Place To Work 14
Slide 15: Oncology Portfolio is accelerating towards the No.1 position
Oncology Portfolio is accelerating towards the No.1 position, supported by innovative science Sales Value (Rs Million)2 Growth IPSOS GR% (MAT DEC 21 vs MAT DEC 20) Percent 1675 38% 37% 21% 23% 24% 353 134% 844 70% AZ Market Top 10 MNC Top 10 Overall 437 49% AZ Rank 5 PY AZ Rank 7 AZ Rank (2019) 10 5
Slide 16: Transforming tomorrow today, bringing meaningful solutions to Relevant Patients
We are Transforming tomorrow today, bringing meaningful solutions to Relevant Patients Transforming Embracing Strengthening Innovative Access Diagnostics Digital Partnerships Programs • India as Hub of Molecular Dx • 4 Digital Channels for HCP • Qure.AI • Patient Navigators • HRD / HRR Gene Panel co
Slide 17: Expanding the disease footprint and leveraging specialties
Expanding the disease footprint and leveraging specialties Establish disease-based approach across CVRM continuum by delivering portfolio value & innovative patient solutions Diabetes Chronic Kidney disease ACS / Heart failure Cardiovascular disease T2DM CKD Stage 1-3, Hyperkalemia ACS-PCI, HFrEF/HF
Slide 18: CVRM continues to make a mark despite genericized portfolio
CVRM continues to make a mark despite genericized portfolio CVRM Growth across Brands* (FY 2021-22) Science Dissemination Intensified 11.2% 850 760 660 • 2270+ science disseminations 4.6% 4% • 10,000+ Audiences Forxiga Mono (Vol) Briilinta (Val) Core CV (Val) Diabetes ACS Core CV CVRM continue to in
Slide 19: R&I Business grew by 82% in the FY 2021-22
R&I Business grew by 82% in the FY 2021-22 Symbicort growing faster than the market. Fasenra adding more Patients QoQ Launched in April 2021, Company’s first monoclonal antibody to target eosinophilic pathway of asthma 35% Market vs. Symbicort(Vol) Patients* onboarded 15 precison clinics# pan India
Slide 20: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 Therapy Area Update 5 COVID-19 Response 6 Sustainability 7 Great Place To Work 20
Slide 21: COVID-19 Response
Like in previous year, our priority is to continue to ensure: COVID-19 Uninterrupted supply of medicines to patients Response Safeguarding the health of adjoining communities Safeguarding the health of our employees 21
Slide 22: Transforming patient lives by accelerating Digital adoption across touchpoints
Transforming patient lives by accelerating Digital adoption across touchpoints Increase HCP reach Learning (whitespace) Transformation Degreed Patient awareness and Digital Supply System of Care wellbeing Chain Patient Support Track & Trace Programs Serialization* AZ PSP Cloud Tech platform to suppo
Slide 23: Impact through digital acceleration
Impact through digital acceleration Objective is to build a digital ecosystem powered by Analytics & Insights that helps AZ to effectively engage HCPs and patients System of Care impact & Digital & F2F Engagement Mix Analytics & Insights Patient Education • 1000+ HCPs active across country on • Phar
Slide 24: AZ India is committed to furthering health care innovation
AZ India is committed to furthering health care innovation Bringing digital, R&D and commercial together to create a home for patient-enabled innovation Project Leveraging AI & cloud based technology to facilitate early Heart Beat diagnosis & intervention in ACS patients Anchor Partners Innovation c
Slide 25: Supporting communities in COVID-19
Supporting communities in COVID-19 Vaccine Hesitancy Program | Back 2 School Collaborated to support ‘COVID Vaccination Campaign’ for end-to- Our ‘Back2School’ campaign’ was curated given a need found at the end outreach in Bawana and Jahangirpuri area of North Delhi to promote ground level where pe
Slide 26: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 Therapy Area Update 5 COVID-19 Response 6 Sustainability 7 Great Place To Work 26
Slide 27: Flagship CSR Campaign
Flagship CSR Campaign Ganga Godavari Initiative Young Health program • Our partner ICS in collaboration with BHU screened 6000+ women for • Expanded the decade+ work from Delhi to Karnataka. Targeting to oral, cervical and breast cancer. Out of which 220 positive suspects reach 50,000 people in Bang
Slide 28: Initiated AZ Forest Grant-A-Wish
Initiated AZ Forest Grant-A-Wish We kick-started the campaign AZ Forest in India taking a small Taking the promise of care forward with an underlying step to plant 5000 trees to convert a denuded area of land into objective of adherence to treatment, AstraZeneca India a lush green region. committed
Slide 29: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 Therapy Area Update 5 COVID-19 Response 6 Sustainability 7 Great Place To Work 29
Slide 30: Recognized as a 'Great Place to Work' four years in a row
as Recognized as a ‘Great Place to Work’ four years in a row INTERNAL PULSE SURVEY 84% 88% 92% Employees believe Employees believe that they have Employees believe AZ demonstrates a AZ is a great place to improved or learned new skills or commitment to the safety and work had a development opportuni
Slide 31: Recognition for AZ's efforts during the pandemic
Recognition for AZ’s efforts during the pandemic Winning few external and internal accolades for the impact created via our initiatives in the communities 31
Slide 32: Key priorities going forward
Key priorities going forward 1 Big & bold ambition to be No.1 Oncology company in India 2 Industry leading organization in scientific leadership & patient centric innovation Fastrack our pipeline to drive launch excellence of new products & indications to 3 accelerate growth 4 Continued focus on bui
Slide 33: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis
AstraZeneca Pharma India — Shareholder Meeting (August 2022) on 6ix